<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354196</url>
  </required_header>
  <id_info>
    <org_study_id>Big PICTURE 2</org_study_id>
    <nct_id>NCT02354196</nct_id>
  </id_info>
  <brief_title>Physicians International CT Utilization Registry 2</brief_title>
  <acronym>Big PICTURE 2</acronym>
  <official_title>Big PICTURE 2: Physicians International CT Utilization Registry 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MDDX LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MDDX LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the total plaque burden, plaque severity and composition of patients undergoing&#xD;
      Cardiac CT who do not have any previous history of CVD. There are two cohorts:&#xD;
&#xD;
        1. A retrospective follow-up for MACE endpoints of patients who underwent a CCTA &gt;1 year&#xD;
           ago as part of the Big PICTURE Trial, who meet the inclusion criteria of Big PICTURE 2.&#xD;
&#xD;
        2. A prospective observational registry of patients referred to undergo CCTA with a 1 and 2&#xD;
           year follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the original BIG PICTURE trial, the analysis of over 6000 subject's CCTA images found&#xD;
      significant differences amongst patients of Arabic and south-east Asian descent, with regard&#xD;
      to plaque burden, severity and composition. Due to the &quot;all-comers&quot; nature of that trial, the&#xD;
      factors of diabetes, previous CVD, and other coronary risk factors were likely confounders in&#xD;
      the results. In this trial, those subject selection is screened to eliminate those factors&#xD;
      with the goal of working with a more homogenous population to perform the plaque analysis.&#xD;
      This study is a multicenter, prospective, post marketing, observational registry study&#xD;
      designed to describe frequency and patterns of various risk factors, indications and findings&#xD;
      in patients who undergo CCTA.&#xD;
&#xD;
      BIG PICTURE 2 (abbreviated as &quot;BP2&quot;) will collect data on patients from a wide variety of&#xD;
      imaging sites (inpatient, outpatient, in-clinic CT machine). While the majority of the sites&#xD;
      are within the US, the data collection will not be limited to US-only sites. A sub study of&#xD;
      BP2 will perform a remote short follow-up questionnaire of subjects who were in the original&#xD;
      Big PICTURE study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Plaque characteristics</measure>
    <time_frame>Immediately after scan</time_frame>
    <description>Total plaque burden, composition, location, severity and myocardial perfusion deficits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE endpoints</measure>
    <time_frame>2 years (or more)</time_frame>
    <description>Standard MACE endpoints</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CCTA</arm_group_label>
    <description>Subjects who underwent a CCTA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CCTA</intervention_name>
    <description>CT of heart to assess coronary disease</description>
    <arm_group_label>CCTA</arm_group_label>
    <other_name>Cardiac CT Angiography</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1000 subjects, 18 or older, no previous CAD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subject Inclusion Criteria&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  No prior CVD&#xD;
&#xD;
          -  No hypertension&#xD;
&#xD;
          -  No Diabetes&#xD;
&#xD;
          -  Body mass index (BMI) &lt;35 kg/m2.&#xD;
&#xD;
        Subject Exclusion Criteria&#xD;
&#xD;
          -  &lt;18 years or older&#xD;
&#xD;
          -  Prior CVD&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Body mass index (BMI) &gt;=30 kg/m2.&#xD;
&#xD;
          -  Diabetes Mellitus Type 1 or 2&#xD;
&#xD;
          -  Current or previous history of smoking&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Planned intervention or bypass surgery&#xD;
&#xD;
          -  Known complex congenital heart disease&#xD;
&#xD;
          -  Planned invasive angiography for reasons other than CAD&#xD;
&#xD;
          -  Non-cardiac illness with life expectancy &lt; 2 years&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Concomitant participation in another clinical trial in which subject is subject to&#xD;
             investigational drug or device&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Allergy to iodinated contrast agent&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 mg/dl or GFR &lt;30 ml/min&#xD;
&#xD;
          -  Baseline irregular heart rhythm&#xD;
&#xD;
          -  Heart rate ≥100 beats per minute&#xD;
&#xD;
          -  Systolic blood pressure ≤90 mm Hg&#xD;
&#xD;
          -  Contraindications to β blockers or nitroglycerin Strategies for Recruitment and&#xD;
             Retention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MDDX</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FACTS</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

